File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Post-treatment serial serum squamous cell carcinoma antigen (SCC) in the monitoring of squamous cell carcinoma of the cervix

TitlePost-treatment serial serum squamous cell carcinoma antigen (SCC) in the monitoring of squamous cell carcinoma of the cervix
Authors
Keywordscervical cancer
monitoring
recurrence
SCC
Issue Date1996
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/
Citation
International Journal Of Gynecological Cancer, 1996, v. 6 n. 2, p. 115-119 How to Cite?
AbstractSerum squamous cell carcinoma antigen (SCC) was raised in 62% of 308 patients with squamous cell carcinoma of the cervix before treatment. Post- treatment SCC levels were raised in 69 patients (22.4%). Retrospective review showed that persistently raised SCC level after treatment was significantly associated with persistent or recurrent disease in squamous cell carcinoma of the cervix. The specificity of persistently raised SCC level in association with recurrent disease was 98.2%. The sensitivity in association with recurrent disease was 74.7%. The positive predictive values was 94.2%. The median lead time for recurrence was 4 months. SCC was raised in 38% of patients with clinical evidence of disease in the vagina. One patient had raised SCC one month prior to clinical detection of vaginal metastasis and was salvaged by an exenterative procedure. SCC was raised in 71-91% of patients with metastatic disease in the lung, lymph nodes or other distant sites. Thus, persistently raised SCC level after treatment of squamous cell carcinoma should alert the clinician to look for recurrent disease especially in distant metastatic sites. Post-treatment raised SCC level was associated with less than 5% 5-year survival rate whereas in patients with normal SCC level, the 5-year survival rate was 87%.
Persistent Identifierhttp://hdl.handle.net/10722/87353
ISSN
2015 Impact Factor: 2.116
2015 SCImago Journal Rankings: 0.830
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorCheng, GTSen_HK
dc.contributor.authorCheng, Den_HK
dc.contributor.authorWong, LCen_HK
dc.contributor.authorMa, HKen_HK
dc.date.accessioned2010-09-06T09:28:34Z-
dc.date.available2010-09-06T09:28:34Z-
dc.date.issued1996en_HK
dc.identifier.citationInternational Journal Of Gynecological Cancer, 1996, v. 6 n. 2, p. 115-119en_HK
dc.identifier.issn1048-891Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87353-
dc.description.abstractSerum squamous cell carcinoma antigen (SCC) was raised in 62% of 308 patients with squamous cell carcinoma of the cervix before treatment. Post- treatment SCC levels were raised in 69 patients (22.4%). Retrospective review showed that persistently raised SCC level after treatment was significantly associated with persistent or recurrent disease in squamous cell carcinoma of the cervix. The specificity of persistently raised SCC level in association with recurrent disease was 98.2%. The sensitivity in association with recurrent disease was 74.7%. The positive predictive values was 94.2%. The median lead time for recurrence was 4 months. SCC was raised in 38% of patients with clinical evidence of disease in the vagina. One patient had raised SCC one month prior to clinical detection of vaginal metastasis and was salvaged by an exenterative procedure. SCC was raised in 71-91% of patients with metastatic disease in the lung, lymph nodes or other distant sites. Thus, persistently raised SCC level after treatment of squamous cell carcinoma should alert the clinician to look for recurrent disease especially in distant metastatic sites. Post-treatment raised SCC level was associated with less than 5% 5-year survival rate whereas in patients with normal SCC level, the 5-year survival rate was 87%.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/en_HK
dc.relation.ispartofInternational Journal of Gynecological Canceren_HK
dc.subjectcervical canceren_HK
dc.subjectmonitoringen_HK
dc.subjectrecurrenceen_HK
dc.subjectSCCen_HK
dc.titlePost-treatment serial serum squamous cell carcinoma antigen (SCC) in the monitoring of squamous cell carcinoma of the cervixen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1048-891X&volume=6&issue=2&spage=115&epage=119&date=1996&atitle=Post-treatment+serial+serum+squamous+cell+carcinoma+antigen+(SCC)+in+the+monitoring+of+squamous+cell+carcinoma+of+the+cervixen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1525-1438.1996.06020115.xen_HK
dc.identifier.scopuseid_2-s2.0-0029920793en_HK
dc.identifier.hkuros9965en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029920793&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue2en_HK
dc.identifier.spage115en_HK
dc.identifier.epage119en_HK
dc.identifier.isiWOS:A1996UC12900007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridCheng, GTS=8049877500en_HK
dc.identifier.scopusauthoridCheng, D=7402806161en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridMa, HK=7403095603en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats